
Sign up to save your podcasts
Or


More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DAPA MI
Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate'
https://www.medscape.com/s/viewarticle/998378
- NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
II. Blood Transfusion Strategy Post MI
In MI With Anemia, Results May Favor Liberal Transfusion: MINT
https://www.medscape.com/viewarticle/998376
- MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983
- REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201
- PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
III. FACTOR XI
Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA
https://www.medscape.com/viewarticle/998418
Asundexian Phase 3 AF Study Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/998665
- Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872
IV. Renal Denervation
FDA Panel Split on Efficacy of Spyral Renal Denervation
https://www.medscape.com/viewarticle/995800
FDA OKs Symplicity Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998664
- SPYRAL HTN OFF MED -- https://doi.org/10.1016/S0140-6736(20)30554-7
- SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6
- SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
By Medscape4.9
862862 ratings
More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DAPA MI
Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate'
https://www.medscape.com/s/viewarticle/998378
- NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
II. Blood Transfusion Strategy Post MI
In MI With Anemia, Results May Favor Liberal Transfusion: MINT
https://www.medscape.com/viewarticle/998376
- MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983
- REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201
- PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
III. FACTOR XI
Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA
https://www.medscape.com/viewarticle/998418
Asundexian Phase 3 AF Study Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/998665
- Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872
IV. Renal Denervation
FDA Panel Split on Efficacy of Spyral Renal Denervation
https://www.medscape.com/viewarticle/995800
FDA OKs Symplicity Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998664
- SPYRAL HTN OFF MED -- https://doi.org/10.1016/S0140-6736(20)30554-7
- SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6
- SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]

1,876 Listeners

320 Listeners

542 Listeners

706 Listeners

501 Listeners

167 Listeners

14 Listeners

16 Listeners

3,387 Listeners

138 Listeners

1,141 Listeners

65 Listeners

520 Listeners

367 Listeners

61 Listeners

25 Listeners

7 Listeners

258 Listeners

440 Listeners

272 Listeners